Top in women’s health: New postpartum depression drug; osteoporosis risk during pregnancy
Click Here to Manage Email Alerts
The FDA has recently announced the approval of Zurzuvae, the first and only oral, once-daily treatment for postpartum depression. Prior to the approval, medication for postpartum depression was only available through IV injection.
Zurzuvae (zuranolone, Sage Pharmaceuticals) is expected to be commercially available in the fourth quarter of 2023, according to the manufacturer. It was the top story in women’s health last week.
Another top story was an exclusive video interview about pregnancy- and lactation-associated osteoporosis and fragility fractures, which can occur without adequate dietary calcium intake.
Read these and more top stories in women’s health below:
FDA approves first oral medication to treat postpartum depression
The FDA approved zuranolone as the first oral treatment for postpartum depression in adults, according to an agency press release. Read more.
VIDEO: Pregnancy, breastfeeding can present rare osteoporosis risk
In this video exclusive, Christopher Kovacs, MD, FRCP, FACP, FACE, talks about osteoporosis and fragility fractures associated with pregnancy and lactation. Watch video.
Most OB/GYN residency programs in US lack dedicated menopause curriculum
Menopause education and resources vary across OB/GYN residency programs in the U.S., with most lacking a dedicated menopause curriculum, according to survey results published in Menopause. Read more.
Infertility may increase odds of severe menopausal symptoms
Midlife women aged 45 years or older with a history of infertility were more likely to experience menopausal symptoms than women without infertility, according to secondary analysis results published in Menopause. Read more.
High completion rates with self-managed medication abortion at 9 to 16 weeks gestation
Women who attempted self-managed medication abortion from 9 to 16 weeks gestation experienced high completion rates, with 23.5% visiting health care professionals to confirm completion or treat complications, researchers reported. Read more.